Diagnostic and prognostic value of BMIPP imaging

Journal of Nuclear Cardiology

Volumn 14, Issue 1, 2007, Pages 111-125

  Chikamori, Taishiro ^a   Yamashina, Akira ^a   Hida, Satoshi ^a   Nishimura, Tsunehiko ^b  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

15 (4 IODOPHENYL) 3 METHYLPENTADECANOIC ACID I 123; GADOLINIUM; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TECHNETIUM 99M; TETROFOSMIN TC 99M; THALLIUM 201;

ACUTE DISEASE; ACUTE HEART INFARCTION; ARTICLE; CHRONIC DISEASE; CONGESTIVE CARDIOMYOPATHY; CONTRAST ENHANCEMENT; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MODEL; FOLLOW UP; HEART FAILURE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; JAPANESE; MYOCARDIAL HIBERNATION; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THORAX PAIN; UNSTABLE ANGINA PECTORIS;

CARDIOMYOPATHIES; FATTY ACIDS; HEART DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; IODINE RADIOISOTOPES; IODOBENZENES; MYOCARDIAL ISCHEMIA; PRACTICE GUIDELINES; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33846572346     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nuclcard.2006.11.007     Document Type: Article

References (99)

1. Beller G.A. The status of nuclear cardiology today. J Nucl Cardiol 13 (2006) 1
2. Goodman M.M., Kirsch G., and Knapp Jr. F.F. Synthesis and evaluation of radioiodinated terminal p-iodophenyl-substituted α- and β-methyl-branched fatty acids. J Med Chem 27 (1984) 390-397
3. 123I)-iodophenyl-pentadecanoic acid, a myocardial imaging agent for evaluating fatty acid metabolism: a multi-center trial. [in Japanese]. Kakuigaku 29 (1992) 413-433
4. Tamaki N., Kusakabe K., Kubo A., Kumazaki T., Shimamoto K., Senda S., et al. Guidelines for clinical use of cardiac nuclear medicine (JCS 2005). [in Japanese]. Circ J 65 Suppl IV (2005) 1125-1202
5. Neely J.R., Rovetto M.J., and Oram J.F. Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis 15 (1972) 289-329
6. Knapp Jr. F.F., and Kropp J. Iodine-123-labeled fatty acids for myocardial SPECT: current status and future perspectives. Eur J Nucl Med 22 (1995) 361-381
7. Fujibayashi Y., Yonekura Y., Takemura Y., Wada K., Matsumoto K., Tamaki N., et al. Myocardial accumulation of iodinated beta-methyl-branched fatty acid analogue, iodine-125-15-(p-iodophenyl)-3-(R,S)methylpentadecanoic acid (BMIPP), in relation to ATP concentration. J Nucl Med 31 (1990) 1818-1822
8. Nohara R., Okuda K., Ogino M., Hosokawa R., Tamaki N., Konishi J., et al. Evaluation of myocardial viability with iodine-123-BMIPP in a canine model. J Nucl Med 37 (1996) 1403-1407
9. Hosokawa R., Nohara R., Fujibayashi Y., Okuda K., Ogino M., Hata T., et al. Myocardial kinetics of iodine-123-BMIPP in canine myocardium after regional ischemia and reperfusion: implications for clinical SPECT. J Nucl Med 38 (1997) 1857-1863
10. Kataoka K., Nohara R., Hosokawa R., Hirai T., Okuda K., Li-Guang C., et al. Myocardial lipid metabolism in compensated and advanced stages of heart failure: evaluation by canine pacing model with BMIPP. J Nucl Med 42 (2001) 124-129
11. Tamaki N., and Morita K. Is BMIPP a sensitive marker for myocardial ischaemic stress?. For. Eur J Nucl Med Mol Imaging 31 (2004) 1031-1033
12. Gropler R.J. Is BMIPP a sensitive marker for myocardial ischaemic stress?. Against. Eur J Nucl Med Mol Imaging 31 (2004) 1033-1037
13. Kobayashi H., Kusakabe K., Momose M., Okawa T., Inoue S., Iguchi N., et al. Evaluation of myocardial perfusion and fatty acid uptake using a single injection of iodine-123-BMIPP in patients with acute coronary syndromes. J Nucl Med 39 (1998) 1117-1122
14. 123I-labeled fatty acid analog. J Nucl Med 42 (2001) 1747-1756
15. Nozaki S., Tanaka T., Yamashita S., Sohmiya K., Yoshizumi T., Okamoto F., et al. CD36 mediates long-chain fatty acid transport in human myocardium: complete myocardial accumulation defect of radiolabeled long-chain fatty acid analog in subjects with CD36 deficiency. Mol Cell Biochem 192 (1999) 129-135
16. Kudoh T., Tamaki N., Magata Y., Konishi J., Nohara R., Iwasaki A., et al. Metabolism substrate with negative myocardial uptake of iodine-123-BMIPP. J Nucl Med 38 (1997) 548-553
17. Higuchi T., Taki J., Nakajima K., Kinuya S., Namura M., and Tonami N. Time course of discordant BMIPP and thallium uptake after ischemia and reperfusion in a rat model. J Nucl Med 46 (2005) 172-175
18. Kawai Y., Tsukamoto E., Nozaki Y., Morita K., Sakurai M., and Tamaki N. Significance of reduced uptake of iodinated fatty acid analogue for the evaluation of patients with acute chest pain. J Am Coll Cardiol 38 (2001) 1888-1894
19. Udelson J.E., Beshansky J.R., Ballin D.S., Feldman J.A., Griffith J.L., Heller G.V., et al. Myocardial perfusion imaging for evaluation and triage of patients with suspected acute cardiac ischemia. A randomized controlled trial. JAMA 288 (2002) 2693-2700
20. Klocke F.J., Baird M.G., Lorell B.H., Bateman T.M., Messer J.V., Berman D.S., et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging. J Am Coll Cardiol 42 (2003) 1318-1333
21. 99mTc-tetrofosmin SPECT and coronary angiography. Circ J 68 (2004) 547-552
22. Suzuki A., Takada Y., Nagasaka M., Kato R., Watanabe T., Shimokata K., et al. Comparison of resting β-methyl-iodophenyl pentadecanoic acid (BMIPP) and thallium-201 tomography using quantitative polar maps in patients with unstable angina. Jpn Circ J 61 (1997) 133-138
23. Tateno M., Tamaki N., Yukihiro M., Kudoh T., Hattori N., Tadamura E., et al. Assessment of fatty acid uptake in ischemic heart disease without myocardial infarction. J Nucl Med 37 (1996) 1981-1985
24. Takeishi Y., Fujiwara S., Atsumi H., Takahashi K., Sukekawa H., and Tomoike H. Iodine-123-BMIPP imaging in unstable angina: a guide for interventional strategy. J Nucl Med 38 (1997) 1407-1411
25. 123I-BMIPP scintigraphy in diagnosis of effort angina pectoris with reference to subsets of the disease. Ann Nucl Med 12 (1998) 139-144
26. Morimoto K., Tomoda H., Yoshitake M., Aoki N., Handa S., and Suzuki Y. Prediction of coronary artery lesions in unstable angina by iodine 123 beta-methyl iodophenyl pentadecanoic acid (BMIPP), a fatty acid analogue, single photon emission computed tomography at rest. Angiology 50 (1999) 639-648
27. Franken P.R., Dendale P., De Geeter F., Demoor D., Bossuyt A., and Block P. Prediction of functional outcome after myocardial infarction using BMIPP and sestamibi scintigraphy. J Nucl Med 37 (1996) 718-722
28. 99mTc-tetrofosmin SPECT imaging. Circ J 69 (2005) 311-319
29. Hashimoto A., Nakata T., Tsuchihashi K., Tanaka S., Fujimori K., and Iimura O. Postischemic functional recovery and BMIPP uptake after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction. Am J Cardiol 77 (1996) 25-30
30. Hambye A.S., Vervaet A., Dobbeleir A., Dendale P., and Franken P. Prediction of functional outcome by quantification of sestamibi and BMIPP after acute myocardial infarction. Eur J Nucl Med 27 (2000) 1494-1500
31. Christian T.F., Schwartz R.S., and Gibbons R.J. Determinants of infarct size in reperfusion therapy for acute myocardial infarction. Circulation 86 (1992) 81-90
32. Kloner R.A., and Jennings R.B. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications. Part 1. Circulation 104 (2001) 2981-2989
33. 123I-BMIPP in myocardial viability studies. J Nucl Med 40 (1999) 707-714
34. Beller G.A., and Zaret B.L. Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease. Circulation 101 (2000) 1465-1478
35. 201Tl myocardial single photon emission computed tomography: a multicenter trial. Ann Nucl Med 12 (1998) 237-248
36. Nakata T., Kobayashi T., Tamaki N., Kobayashi H., Wakabayashi T., Shimoshige S., et al. Prognostic value of impaired myocardial fatty acid uptake in patients with acute myocardial infarction. Nucl Med Commun 21 (2000) 897-906
37. 123I-BMIPP in patients with acute myocardial infarction treated with primary percutaneous coronary intervention. Eur J Nucl Med Mol Imaging 31 (2004) 1512-1521
38. Allman K.C., Shaw L.J., Hachamovitch R., and Udelson J.E. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 39 (2002) 1151-1158
39. Pache J., Kastrati A., Mehilli J., Schühlen H., Dotzer F., Hausleiter J., et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 41 (2003) 1283-1288
40. Tsuchihashi M., Tsutsui H., Shihara M., Tada H., Kono S., Takeshita A., et al. Comparison of outcome for patients undergoing balloon angioplasty vs coronary stenting for acute myocardial infarction. Results from nationwide Japanese registry. Circ J 67 (2003) 369-374
41. Fujiwara S., Takeishi Y., Atsumi H., Takahashi K., and Tomoike H. Fatty acid metabolic imaging with iodine-123-BMIPP for the diagnosis of coronary artery disease. J Nucl Med 38 (1997) 175-180
42. Fleischmann K.E., Hunink M.G.M., Kuntz K.M., and Douglas P.S. Exercise echocardiography or exercise SPECT imaging?. A meta-analysis of diagnostic test performance. JAMA 280 (1998) 913-920
43. Hatano T., Chikamori T., Usui Y., Morishima T., Hida S., and Yamashina A. Diagnostic significance of positive I-123 BMIPP despite negative stress Tl-201 myocardial imaging in patients with suspected coronary artery disease. Circ J 70 (2006) 184-189
44. 123I]-iodophenyl-pentadecanoic acid identifies ischemic memory after demand ischemia. Circulation 112 (2005) 2169-2174
45. Iskandrian A.S., Heo J., Askenase A., Segal B.L., and Auerbach N. Dipyridamole cardiac imaging. Am Heart J 115 (1988) 432-443
46. Johnston D.L., Daley J.R., Hodge D.O., Hopfenspirger M.R., and Gibbons R.J. Hemodynamic responses and adverse effects associated with adenosine and dipyridamole pharmacologic stress testing: a comparison in 2000 patients. Mayo Clin Proc 70 (1995) 331-336
47. Nishimura M., Hashimoto T., Kobayashi H., Fukuda T., Okino K., Yamamoto N., et al. Myocardial scintigraphy using a fatty acid analogue detects coronary artery disease in hemodialysis patients. Kidney Int 66 (2004) 811-819
48. Chikamori T., Fujita H., Nanasato M., Toba M., and Nishimura T. Prognostic value of I-123 15-(p-iodophenyl)-3-(R,S) methylpentadecanoic acid myocardial imaging in patients with known or suspected coronary artery disease. J Nucl Cardiol 12 (2005) 172-178
49. Berman D.S., Hachamovitch R., Kiat H., Cohen I., Cabico J.A., Wang F.D., et al. Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol 26 (1995) 639-647
50. Matsuki T., Tamaki N., Nakata T., Doi A., Takahashi H., Iwata M., et al. Prognostic value of fatty acid imaging in patients with angina pectoris without prior myocardial infarction: comparison with stress thallium imaging. Eur J Nucl Med Mol Imaging 31 (2004) 1585-1591
51. Cohn P.F. Prognosis in exercise-induced silent myocardial ischemia and implications for screening asymptomatic populations. Prog Cardiovasc Dis 34 (1992) 399-412
52. 123I-BMIPP uptake implies decreased myocardial flow reserve in patients with chronic stable angina. Eur J Nucl Med Mol Imaging 33 (2006) 6-12
53. Tamaki N., Tadamura E., Kudoh T., Hattori N., Yonekura Y., Nohara R., et al. Prognostic value of iodine-123 labeled BMIPP fatty acid analogue imaging in patients with myocardial infarction. Eur J Nucl Med 23 (1996) 272-279
54. Hamilton K.K., and Pepine C.J. A renaissance of provocative testing for coronary spasm?. J Am Coll Cardiol 35 (2000) 1857-1859
55. Beltrame J.F., Sasayama S., and Maseri A. Racial heterogeneity in coronary artery vasomotor reactivity: differences between Japanese and Caucasian patients. J Am Coll Cardiol 33 (1999) 1442-1452
56. Nakajima K., Shimizu K., Taki J., Uetani Y., Konishi S., Tonami N., et al. Utility of iodine-123-BMIPP in the diagnosis and follow-up of vasospastic angina. J Nucl Med 36 (1995) 1934-1940
57. Watanabe K., Takahashi T., Miyajima S., Hirokawa Y., Tanabe N., Kato K., et al. Myocardial sympathetic denervation, fatty acid metabolism, and left ventricular wall motion in vasospastic angina. J Nucl Med 43 (2002) 1476-1481
58. Sakata K., Shirotani M., Yoshida H., and Kurata C. Iodine-123 metaiodobenzylguanidine cardiac imaging to identify and localize vasospastic angina without significant coronary artery narrowing. J Am Coll Cardiol 30 (1997) 370-376
59. Inobe Y., Kugiyama K., Miyagi H., Ohgushi M., Tomiguchi S., Takahashi M., et al. Long-lasting abnormalities in cardiac sympathetic nervous system in patients with coronary spastic angina: quantitative analysis with iodine 123 metaiodobenzylguanidine myocardial scintigraphy. Am Heart J 134 (1997) 112-118
60. Udelson J.E., Bonow R.O., and Dilsizian V. The historical and conceptual evolution of radionuclide assessment of myocardial viability. J Nucl Cardiol 11 (2004) 318-334
61. Chareonthaitawee P., Gersh B.J., Araoz P.A., and Gibbons R.J. Revascularization in severe left ventricular dysfunction. The role of viability testing. J Am Coll Cardiol 46 (2005) 567-574
62. Matsunari I., Fujino S., Taki J., Senma J., Aoyama T., Wakasugi T., et al. Impaired fatty acid uptake in ischemic but viable myocardium identified by thallium-201 reinjection. Am Heart J 131 (1996) 458-465
63. Shimonagata T., Nanto S., Kusuoka H., Ohara T., Inoue K., Yamada S., et al. Metabolic changes in hibernating myocardium after percutaneous transluminal coronary angioplasty and the relation between recovery in left ventricular function and free fatty acid metabolism. Am J Cardiol 82 (1998) 559-563
64. Taki J., Nakajima K., Matsunari I., Bunko H., Takata S., Kawasuji M., et al. Assessment of improvement of myocardial fatty acid uptake and function after revascularization using iodine-123-BMIPP. J Nucl Med 38 (1997) 1503-1510
65. Hambye A.S.E., Dobbeleir A.A., Vervaet A.M., Van den Heuvel P.A., and Franken P.R. BMIPP imaging to improve the value of sestamibi scintigraphy for predicting functional outcome in severe chronic ischemic left ventricular dysfunction. J Nucl Med 40 (1999) 1468-1476
66. 123I-BMIPP SPECT. Chest 117 (2000) 65-72
67. Dilsizian V., Rocco T.P., Freedman N.M.T., Leon M.B., and Bonow R.O. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 323 (1990) 141-146
68. Nohria A., Lewis E., and Stevenson L.W. Medical management of advanced heart failure. JAMA 287 (2002) 628-640
69. Gradman A., Deedwania P., Cody R., Massie B., Packer M., Pitt B., et al. Predictors of total mortality and sudden death in mild to moderate hear failure. J Am Coll Cardiol 14 (1989) 564-570
70. Shamagian L.G., Gonzalez-Juanatey J.R., Roman A.V., Acuna J.M.G., and Lamela A.V. The death rate among hospitalized heart failure patients with normal and depressed left ventricular ejection fraction in the year following discharge: evolution over a 10-year period. Eur Heart J 26 (2005) 2251-2258
71. Rector T.S., Olivari M.T., Levine T.B., Francis G.S., and Cohn J.N. Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration. Am Heart J 114 (1987) 148-152
72. Packer M. Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure?. Circulation 108 (2003) 2950-2953
73. Marlet P., Valette H., Dubois-Randé J.L., Moyse D., Duboc D., and Dove P. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 33 (1992) 471-477
74. Imamura Y., Ando H., Mitsuoka W., Egashira S., Masaki H., Ashihara T., et al. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underling cause. J Am Coll Cardiol 26 (1995) 1594-1599
75. Sasaki R., Mitani I., Usui T., Kitamura Y., Yoshii Y., Ishikawa T., et al. Clinical value of iodine-123 beta-methyliodophenyl pentadecanoic acid (BMIPP) myocardial single photon emission computed tomography for predicting cardiac death among patients with chronic heart failure. Circ J 67 (2003) 918-924
76. 123I)iodophenyl pentadecanoic acid) myocardial single photon emission computed tomography. Ann Nucl Med 10 (1996) 71-78
77. Ohtsuki K., Sugihara H., Kuribayashi T., and Nakagawa M. Impairment of BMIPP accumulation at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. J Nucl Med 40 (1999) 2007-2013
78. O'Gara P.T., Bonow R.O., Maron B.J., Damske B.A., Lingen A.V., Bacharach S.L., et al. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. Circulation 76 (1987) 1214-1223
79. Takata J., Counihan P.J., Gane J.N., Doi Y., Chikamori T., Ozawa T., et al. Regional thallium-201 washout and myocardial hypertrophy in hypertrophic cardiomyopathy and its relation to exertional chest pain. Am J Cardiol 72 (1993) 211-217
80. Yamada M., Elliott P.M., Kaski J.C., Prasad K., Gane J.N., Lowe C.M., et al. Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy: relationship to clinical presentation and outcome. Eur Heart J 19 (1998) 500-507
81. Maron B.J., McKenna W.J., Danielson G.K., Kappenberger L.J., Kuhn H.J., Seidman C.E., et al. ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 24 (2003) 1965-1991
82. Choudhury L., Mahrholdt H., Wagner A., Choi K.M., Elliott M.D., Klocke F.J., et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40 (2002) 2156-2164
83. Moon J.C.C., McKenna W.J., McCrohon J.A., Elliott P.M., Smith G.C., and Pennell D.J. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 41 (2003) 1561-1567
84. Amano Y., Kumita S., Takayama M., and Kumazaki T. Comparison of contrast-enhanced MRI with iodine-123 BMIPP for detection of myocardial damage in hypertrophic cardiomyopathy. AJR Am J Roentgenol 185 (2005) 312-318
85. Bulkley B.H., Hutchins G.M., Bailey I., Strauss H.W., and Bertram P. Thallium 201 imaging and gated cardiac blood pool scans in patients with ischemic and idiopathic congestive cardiomyopathy. Circulation 55 (1977) 753-760
86. Saltissi S., Hockings B., Croft D.N., and Webb-Peploe M.M. Thallium-201 myocardial imaging in patients with dilated and ischaemic cardiomyopathy. Br Heart J 46 (1981) 290-295
87. Dunn R.F., Uren R.F., Sadick N., Bautovich G., McLaughlin A., Hiroe M., et al. Comparison of thallium 201 scanning in idiopathic dilated cardiomyopathy and severe coronary artery disease. Circulation 66 (1982) 804-810
88. Eichhorn E.J., Kosinski E.J., Lewis S.M., Hill T.C., Emond L.H., and Leland S. Usefulness of dipyridamole-thallium-201 perfusion scanning for distinguishing ischemic from nonischemic cardiomyopathy. Am J Cardiol 62 (1988) 945-951
89. Chikamori T., Doi Y.L., Yonezawa Y., Yamada M., Seo H., and Ozawa T. Value of dipyridamole thallium-201 imaging in noninvasive differentiation of idiopathic dilated cardiomyopathy from coronary artery disease with left ventricular dysfunction. Am J Cardiol 69 (1992) 650-653
90. Tauberg S.G., Orie J.E., Bartlett B.E., Cottington E.M., and Flores A.R. Usefulness of thallium-201 for distinction of ischemic from idiopathic dilated cardiomyopathy. Am J Cardiol 71 (1993) 674-680
91. 123I BMIPP SPECT: correlation with clinicopathological findings and clinical course. Heart 81 (1999) 153-159
92. Ito T., Hoshida S., Nishio M., Aoi T., Egami Y., Takeda T., Kawabata M., et al. Relationship between evaluation by quantitative fatty acid myocardial scintigraphy and response to β-blockade therapy in patients with dilated cardiomyopathy. Eur J Nucl Med 28 (2001) 1811-1816
93. Grines C.L., Browne K.F., Marco J., Rothbaum D., Stone G.W., O'Keefe J., et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 328 (1993) 673-679
94. Yasuno M., Saito Y., Ishida M., Suzuki K., Endo S., and Takahashi M. Effects of percutaneous transluminal coronary angioplasty: intracoronary thrombolysis with urokinase in acute myocardial infarction. Am J Cardiol 53 (1984) 1217-1220
95. Iga K., Hori K., Kitaguchi K., Matsumura T., Gen H., Tomonaga G., et al. Transient segmental asynergy of the left ventricle of patients with various clinical manifestations possibly unrelated to the coronary artery disease. Jpn Circ J 55 (1991) 1061-1067
96. Tsuchihashi K., Ueshima K., Uchida T., Oh-mura N., Kimura K., Owa M., et al. Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction. J Am Coll Cardiol 38 (2001) 11-18
97. Wittstein I.S., Thiemann D.R., Lima J.A.C., Baughman K.L., Schulman S.P., Gerstenblith G., et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 352 (2005) 539-548
98. Moon J.C.C., Fisher N.G., McKenna W.J., and Pennell D.J. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with nondiagnostic echocardiography. Heart 90 (2004) 645-649
99. 99mTc-PYP myocardial SPECT. Ann Nucl Med 19 (2005) 435-445